Suppr超能文献

含已知效应药用辅料的药物:一项法国综述。

Medicines containing pharmaceutical excipients with known effects: a French review.

作者信息

Fusier Isabelle, Tollier Corinne, Husson Marie Caroline

机构信息

Centre National Hospitalier d'Information sur le Médicament, CNHIM-Hôpital de Bicêtre, 78, rue du général Leclerc, BP11, 94272 Le Kremlin Bicêtre, France.

出版信息

Pharm World Sci. 2003 Aug;25(4):152-5. doi: 10.1023/a:1024815412228.

Abstract

OBJECTIVE

The 13/01/01 French decree published an official list of brands and their generic drugs and identified 38 groups of excipients with known effects which are responsible for side effects and contraindication respectively. Our objective was to review all medicines marketed in France containing these excipients and to disseminate this information to French health care practitioners.

METHOD

The side effects and contraindications regarding these excipients have been documented in the French drug database Thériaque (http://www.theriaque.org). They were documented for each medicine containing these excipients in addition to the data mentioned in the Summary of Product Characteristics (SPC). Results were obtained on 1 June 2001 by using computerised queries from the database.

RESULTS

Within the 38 groups, 300 specific excipients and derivatives with known effects were identified. Among the 8900 medicines (100%), 5567 medicines (62.6%) contained one or more of these excipients; 2483 contained 1 excipient, 1819 contained 2 excipients and 1265 contained 3 or more excipients; 410 side effects or contra-indications--were described according to the route of administration and the threshold dose. They were linked to these 5567 medicines; 5818 excipients with a threshold dose were mentioned in the 'composition' sections of these 5567 medicines. Among these 5818 excipients, 3385 quantitative doses were documented in the SPCs or EPARs.

CONCLUSION

This review shows the extent of most of the excipients contained in medicines marketed in France. The dissemination of these data offsets the lack of information in the SPCs.

摘要

目的

2001年1月13日法国颁布的法令公布了药品品牌及其通用名的官方清单,并确定了38组已知有作用的辅料,它们分别是副作用和禁忌的成因。我们的目的是审查在法国销售的所有含有这些辅料的药品,并将此信息传播给法国的医疗从业者。

方法

关于这些辅料的副作用和禁忌已记录在法国药品数据库Thériaque(http://www.theriaque.org)中。除了产品特性摘要(SPC)中提到的数据外,还针对每种含有这些辅料的药品进行了记录。2001年6月1日通过对数据库进行计算机查询获得了结果。

结果

在这38组中,确定了300种具有已知作用的特定辅料及其衍生物。在8900种药品中(100%),5567种药品(62.6%)含有一种或多种这些辅料;2483种含有1种辅料,1819种含有2种辅料,1265种含有3种或更多辅料;根据给药途径和阈剂量描述了410种副作用或禁忌,它们与这5567种药品相关;在这5567种药品的“成分”部分提到了5818种有阈剂量的辅料。在这5818种辅料中,3385种定量剂量记录在SPC或欧洲公共评估报告(EPAR)中。

结论

这项审查显示了法国市场上销售的药品中大多数辅料的情况。这些数据的传播弥补了SPC中信息的不足。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验